TITLE

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients

AUTHOR(S)
KOUJI IZUMI; SHINGO ITAI; YOSHIKO TAKAHASHI; AERKEN MAOLAKE; MIKIO NAMIKI
PUB. DATE
July 2014
SOURCE
Oncology Letters;2014, Vol. 8 Issue 1, p305
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that demonstrate optimal efficacy against this type of HT. The charts of 50 cases of patients that had received VEGFR-TKI treatment were retrospectively examined. The association between patient background and TKI-induced HT, and the effect of administering AHTA were analyzed. High systolic blood pressure at baseline was identified to be a predictive factor for HT. In addition, there was no difference observed between calcium channel blockers (CCBs) and angiotensin receptor II blockers (ARBs) as first-line AHTA for the control of HT. The findings of the present study may aid with predicting the onset of TKI-induced HT, as well as for its management via the primary use of either CCBs or ARBs.
ACCESSION #
110397724

 

Related Articles

  • Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib. Richter, Suzanne; Jo-An Seah; Pond, Gregory R.; Gan, Hui K.; Mackenzie, Mary J.; Hotte, Sebastien J.; Mukherjee, Som D.; Murray, Nevin; Kollmannsberger, Christian; Heng, Daniel; Haider, Masoom A.; Halford, Robert; Ivy, S. Percy; Moore, Malcolm J.; Sridhar, Srikala S. // Canadian Urological Association Journal;nov/dec2014, Vol. 8 Issue 11/12, p398 

    Introduction: Pivotal phase III trials have positioned angiogenesis inhibitors as first-line therapy for the management of most advanced or metastatic renal cell carcinomas (mRCC). Approaches to secondline therapy, however, remain more controversial with respect to drug selection and drug...

  • Sunitinib.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p189 

    The article presents case studies of two men and a woman, aged between 57-65 years, who developed hypertension, asthenia or hand-foot syndrome during treatment with sunitinib.

  • Millions of mild hypertensives.  // British Medical Journal;10/18/1980, Vol. 281 Issue 6247, p1024 

    Examines the treatment for mild hypertensive in Great Britain. Management of blood pressure levels; Cautions on the fatal and non-fatal complications; Efficacy of drugs as treatment.

  • Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.  // Current Medical Literature: Kidney Cancer;Mar2011, Vol. 3 Issue 1, p18 

    The article offers information on the study of M. H. Kappers and colleagues on the role of tyrosine kinase inhibitor sunitib on hypertension. The study shows that application of sunitib to increase endothelin-1 levels of vascular origin. It says that hypertension induced by sunitib is caused by...

  • A NEW BASE LINE FOR THE EVALUATION OF ANTIHYPERTENSIVES. Grenfell, Raymond F.; Briggs, Arthur H.; Holland, William C. // Angiology;Nov1962, Vol. 13 Issue 11, p495 

    In the parenteral placebo group, there was a significant decrease in the systolic blood pressure for 63 weeks and in the diastolic blood pressure for 147 weeks when compared to the blood pressure in week 0 of treatment. There was a significant decrease in the systolic blood pressure in these...

  • Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review. Bramlage, Peter; Hasford, Joerg // Cardiovascular Diabetology;2009, Vol. 8, p1 

    Background: Blood pressure lowering drugs are usually evaluated in short term trials determining the absolute blood pressure reduction during trough and the duration of the antihypertensive effect after single or multiple dosing. A lack of persistence with treatment has however been shown to be...

  • Erratum to: ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients. Volpe, Massimo; Sierra, Alejandro; Kreutz, Reinhold; Laurent, St├ęphane; Manolis, Athanasios // High Blood Pressure & Cardiovascular Prevention;Jun2014, Vol. 21 Issue 2, p149 

    A correction to the article "ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients" that was published online on March 29, 2014 is presented.

  • Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Fessel, Joshua P.; Hamid, Rizwan; Wittmann, Bryan M.; Robinson, Linda J.; Blackwell, Tom; Tada, Yuji; Tanabe, Nobuhiro; Tatsumi, Koichiro; Hemnes, Anna R.; West, James D. // Pulmonary Circulation;2012, Vol. 2 Issue 2, p201 

    Pulmonary arterial hypertension (PAH) is a progressive and fatal disease of the lung vasculature for which the molecular etiologies are unclear. Specific metabolic alterations have been identified in animal models and in PAH patients, though existing data focus mainly on abnormalities of glucose...

  • An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Asahina, Hajime; Tamura, Yosuke; Nokihara, Hiroshi; Yamamoto, Noboru; Seki, Yoshitaka; Shibata, Takashi; Goto, Yasushi; Tanioka, Maki; Yamada, Yasuhide; Coates, Andrew; Chiu, Yi-Lin; Li, Xiaohui; Pradhan, Rajendra; Ansell, Peter; McKeegan, Evelyn; McKee, Mark; Carlson, Dawn; Tamura, Tomohide // Cancer Chemotherapy & Pharmacology;Jun2012, Vol. 69 Issue 6, p1477 

    Purpose: This phase 1 study assessed the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of linifanib in Japanese patients with advanced solid tumors. Methods: Patients were assigned to one of four sequential cohorts (0.05, 0.10, 0.20, or 0.25 mg/kg) of oral,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics